Biomet Plaintiffs Anticipating 2015 Trials
In a recent Scheduling Order, the Judge presiding over the multidistrict litigation (MDL) which centralizes Biomet hip replacement lawsuits has established trial dates for the bellwether cases. These cases are proceeding in the U.S. District Court for the Northern District of Indiana before Judge Robert L. Miller. The MDL consolidates cases filed against the manufacturer with common complaints of side… Read more »
Bellwether Cases May be Delayed in Granuflo Litigation
A December 16 motion filed by plaintiffs and defendants in the coordinated Granuflo MDL has requested additional time for selecting bellwether cases in the consolidated proceedings. “In as much as generic discovery is only beginning, the parties are not yet in a position to propose a realistic schedule for case specific discovery and the selection of bellwether cases,” states the… Read more »
Tylenol Lawsuit Loans Assist Plaintiffs in MDL
Plaintiffs with Tylenol lawsuits currently pending in multidistrict litigation in Pennsylvania have moved forward another small step. A status conference was held on December 17 to discuss some of the specifics of the nearly 100 cases currently pending in U.S. District Court. Those with pending cases may find that Tylenol lawsuit loans help to ease the financial pinch while they… Read more »
Merck Proposes Settlement of Fosamax Jaw Claims
There was some potential good news for plaintiffs suing Merck & Co., Inc., due to complications from their osteoporosis drug, Fosamax. The company announced December 9 it was willing to pay $27.7 million to settle lawsuits by hundreds of plaintiffs who allege they suffered jaw deterioration to their use of Fosamax. The fate of the proposal is unknown. Plaintiffs involved… Read more »
Risperdal Settlement Loans an Option for Plaintiffs
After allegations involving Johnson & Johnson’s Risperdal came to light, the U.S. Department of Justice (DOJ) launched an investigation into the company and its marketing tactics. The DOJ found that J&J had illegally marketed Risperdal, a psychiatric medication, for off-label uses and that they had marketed the drug toward an inappropriate demographic. Johnson & Johnson recently agreed to an astronomical… Read more »
